According to Zacks, “Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn’s disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103). “
Several other equities analysts have also issued reports on the company. ValuEngine upgraded Zumiez from a “sell” rating to a “hold” rating in a research report on Monday, July 22nd. Ascendiant Capital Markets set a $23.00 target price on REDHILL BIOPHAR/S and gave the company a “buy” rating in a research note on Monday, July 8th. Finally, WBB Securities upgraded REDHILL BIOPHAR/S from a “buy” rating to a “strong-buy” rating and set a $17.00 target price on the stock in a research note on Friday, July 12th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $17.85.
REDHILL BIOPHAR/S (NASDAQ:RDHL) last issued its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.04. REDHILL BIOPHAR/S had a negative return on equity of 93.55% and a negative net margin of 561.47%. The business had revenue of $1.74 million during the quarter, compared to analyst estimates of $2.98 million. Sell-side analysts expect that REDHILL BIOPHAR/S will post -1.43 EPS for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC lifted its stake in REDHILL BIOPHAR/S by 69.9% in the 4th quarter. Millennium Management LLC now owns 301,693 shares of the biotechnology company’s stock valued at $1,674,000 after acquiring an additional 124,072 shares in the last quarter. Ibex Investors LLC raised its stake in shares of REDHILL BIOPHAR/S by 3.9% during the 1st quarter. Ibex Investors LLC now owns 975,928 shares of the biotechnology company’s stock worth $8,110,000 after purchasing an additional 36,914 shares in the last quarter. ARK Investment Management LLC raised its stake in shares of REDHILL BIOPHAR/S by 8.5% during the 1st quarter. ARK Investment Management LLC now owns 65,918 shares of the biotechnology company’s stock worth $548,000 after purchasing an additional 5,177 shares in the last quarter. Geode Capital Management LLC bought a new stake in shares of REDHILL BIOPHAR/S during the 4th quarter worth approximately $73,000. Finally, FMR LLC bought a new stake in shares of REDHILL BIOPHAR/S during the 4th quarter worth approximately $1,110,000. Hedge funds and other institutional investors own 35.63% of the company’s stock.
About REDHILL BIOPHAR/S
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company's clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors.
Further Reading: How a Put Option Works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.